Mammoth Biosciences: Funding, Investors & Team (Sep 2026)
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber. Mammoth has also been working on developing a rapid COVID-19 test.
Mammoth Biosciences has raised $150M across 1 funding round on record, the most recent a Series D of $150M announced in Sep 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mammoth Biosciences Company Profile and Key Stats
Latest funding round on record: Sep 2021.
Mammoth Biosciences Funding Rounds
Mammoth Biosciences Founders and Leadership Team
Contact details for the Mammoth Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →Mammoth Biosciences Funding Compared to Other Biotechnology Startups
Mammoth Biosciences' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mammoth Biosciences in Biotechnology and San Francisco
Companies Similar to Mammoth Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Mammoth Biosciences Funding FAQs
What does Mammoth Biosciences do?
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber. Mammoth has also been working on developing a rapid COVID-19 test.
How much funding has Mammoth Biosciences raised?
Mammoth Biosciences has raised $150M across 1 round on record. The most recent is a Series D of $150M announced in Sep 2021.
When did Mammoth Biosciences last raise funding?
Mammoth Biosciences' most recent funding round on record is a Series D of $150M, announced in Sep 2021.
Who is the CEO of Mammoth Biosciences?
Trevor Martin is listed as CEO at Mammoth Biosciences.
Where is Mammoth Biosciences headquartered?
Mammoth Biosciences is based in San Francisco, California, United States.
How many employees does Mammoth Biosciences have?
Mammoth Biosciences is in the 101-250 employee band.
How does Mammoth Biosciences' funding compare to other Biotechnology startups?
Mammoth Biosciences' latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Mammoth Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mammoth Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.